title: Safety of prostaglandin E1 for the treatment of peripheral arterial occlusive disease in patients with congestive heart failure. The Alprostadil Investigators.
abstract: OBJECTIVE
  To confirm the safety of prostaglandin E ( 1 ) (PGE ( 1 ) ) when administered in 100 mL normal saline to patients with severe peripheral occlusive disease (PAOD; Fontaine class III or IV) and concomitant compensated chronic congestive heart failure (CHF) and to explore possible hemodynamic benefits of PGE ( 1 ) in CHF.
  
  
  BACKGROUND
  PGE ( 1 ) has been found to be effective in the treatment of severe PAOD. The agent may beneficially affect left ventricular performance or hemodynamics in patients with CHF. However, it must be administered intravenously (in saline diluent, adding potential hazard in patients with volume CHF).
  
  
  METHODS
  In a randomized, double-blinded protocol, 50 patients received intravenous (i.v.) infusion of either 60 microg PGE ( 1 ) or placebo, each dissolved in 100 mL saline solution administered over 2 hours each day for 14 days. During the succeeding 14 days, i.v. PGE ( 1 ) was administered to all patients in open-label fashion. Safety was assessed by clinical evaluation of symptoms and signs of CHF or other adverse events, by catheter-based and echocardiographic search for objective cardiac functional influences, and by echocardiogram monitoring for cardiac rhythm. PAOD status also was defined.
  
  
  RESULTS
  No evidence of clinical or objective cardiac functional influence was detected. With the usual dosage approved in PAOD, no significant influence on cardiac performance was observed.
  
  
  CONCLUSIONS
  PGE ( 1 ) is safe for treatment of PAOD in patients with concomitant chronic, compensated CHF.
authors.affiliation: Department of Cardiology, Barzilai Medical Center, Ben Gurion University of the Negev, Ashkelon, Israel.
authors.forename: L
authors.initials: L
authors.lastname: Reisin
authors.forename: A
authors.initials: A
authors.lastname: Marmor
authors.forename: B
authors.initials: B
authors.lastname: Rabinowitz
authors.forename: P J
authors.initials: PJ
authors.lastname: Bernink
authors.forename: A
authors.initials: A
authors.lastname: Caspi
authors.forename: W
authors.initials: W
authors.lastname: Ruzyllo
authors.forename: J S
authors.initials: JS
authors.lastname: Borer
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000527:Alprostadil / Q000009:adverse effects*; D001157:Arterial Occlusive Diseases / Q000188:drug therapy*; D004311:Double-Blind Method; D005260:Female; D006333:Heart Failure / Q000503:physiopathology*; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D016491:Peripheral Vascular Diseases / Q000188:drug therapy*; D016277:Ventricular Function, Left / Q000187:drug effects
chemical_list: D000527:Alprostadil